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Abstract
Background: CD4 testing is, and will remain an important part of HIV treatment and care in low and middle
income countries (LMICs). We report the findings of a systematic review assessing acceptability and feasibility of
POC CD4 testing in field settings.
Methods: Electronic databases were searched for studies published in English between 2005 and 2015 that describe
POC CD4 platforms. Studies conducted in LMICs and under field conditions outside a laboratory environment were
eligible. Qualitative and descriptive data analysis was used to present the findings.
Results: Twelve studies were included, 11 of which were conducted in sub-Saharan countries and used one POC CD4
test (The Alere Pima CD4). Patients reported positively regarding the implementation of POC CD4 testing at primary
health care and community level with ≥90 % of patients accepting the test across various study settings. Health service
providers expressed preference toward POC CD4 testing as it is easy-to-use, efficient and satisfied patients’ needs to a
greater extent as compared to conventional methods. However, operational challenges including preference toward
venous blood rather than finger-prick sampling, frequent device failures and operator errors, quality of training for test
operators and supervisors, and increased staff workload were also identified.
Conclusions: POC CD4 testing seems acceptable and feasible in LIMCs under field conditions. Further studies using
different POC CD4 tests available on the market are required to provide critical data to support countries in selection
and implementation of appropriate POC CD4 technologies.
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Background
For many years, CD4 count testing has been a key diag-
nostic tool to identify HIV positive patients eligible for
antiretroviral therapy (ART) and monitoring patient re-
sponses to treatment. Recently, in light of new evidence
supporting early treatment [1], there is a movement in
policy recommendation and practice towards CD4-
independent ART initiation and a number of countries
have already approved treatment for all HIV infected in-
dividuals regardless of their CD4 count. However, in the
near future, CD4 counts still remain an important and
practical part of HIV care particularly in decision making
around ART initiation, clinical management and treat-
ment monitoring in many countries where access to viral
load monitoring remains limited [2].
Availability and access to CD4 count testing has been
identified as a major barrier for increasing access to ART
particularly in low-resource settings where laboratory
based CD4 monitoring is not always available or easy to
access [3]. The lack of reliable and affordable tests in these
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settings leads to missed opportunities of early ART initi-
ation and significant patient loss-to-follow up [4].
Point-of-care (POC) CD4 testing has been introduced
as an approach to overcome this challenge, possessing
major advantages as compared to standard laboratory-
based CD4 testing by flow cytometry in primary health-
care settings that lack infrastructure support and ab-
sence of well-functioning patient and/or sample referral
systems [5]. Results from recent field studies suggest
that POC CD4 tests are reliable [6–8], can help to in-
crease the likelihood of an infected person having their
CD4 T-cell count measured and receive the result [9],
reduce time from HIV testing to ART initiation [10, 11],
facilitate rapid (same day) ART initiation among patients
eligible for treatment [12, 13], reduce loss to follow up
[11], and most importantly, provide an immediate CD4
count which can significantly improve patient retention
on care [14].
However, there is lack of synthesis of available evi-
dence regarding operation and implementation of POC
technologies in field settings. We conducted a systematic
review to assess acceptability and feasibility of currently
available or prototype commercial POC CD4 tests and
to identify evidence gaps from field evaluations with a
geographical focus in resource-constrained settings.
Methods
Literature search strategy
This review was conducted following the requirements
of the preferred reporting items for systematic reviews
and meta-analyses (PRISMA). A literature search using
established search terms was first conducted in Medline
to identify any study describing POC CD4 tests con-
ducted in low and middle income countries (LMICs)
published between Jan 2005 – Jan 2015 in English (see
Additional file 1). The search strategy was then adapted
by using the appropriate subject thesauri where available
and modifying the search syntax to the relevant software
platforms, and was undertaken across other electronic da-
tabases including: Embase, CENTRAL, Cinahl, PsycINFO,
Biological Abstracts, Scopus and Web of Science. Searches
were also conducted in grey literature resources and
hand-searching of reference lists and citation was per-
formed to identify relevant studies.
Study selection
Study inclusion criteria were defined using PICO (partic-
ipants, interventions, comparisons, outcomes) format
[15]. Participants (P) included HIV positive, HIV nega-
tive and unknown HIV status persons aged ≥ 12 months.
For intervention (I), any of the following six commer-
cially available POC CD4 testing platforms listed in the
UNITAID “2014 HIV/AIDS Diagnosis Technology
Landscape” report [16] were included: (1) PointCare
NOW™ (PointCare Technology Inc, Marlborough, MA,
USA); (2) Pima™ CD4 (Alere Inc, Waltham, MA, USA);
(3) Daktari™ CD4 Counter (Daktari Diagnostics Inc,
Cambridge MA, USA); (4) CyFlow® CD4 miniPOC
(Partec, Munich, Germany); (5) BD FACSPresto™ (BD
Biosciences, San Jose, CA, USA); and (6) MyT4™ CD4
Test (Zyomyx Inc, Fremont, CA, USA). Comparators/
controls (C): Laboratory based CD4 test (Flow Cytome-
try) if applicable with outcomes (O) of interest contain-
ing information on acceptability, feasibility of POC
CD4 testing in field settings (Fig. 1).
Data extraction and data synthesis
A pre-constructed electronic data extraction form was
developed, pre-tested and finalized by consensus among
authors. Data extraction was conducted by one reviewer
and verified by the second using the data extraction
form with 20 % duplicate extraction (Five papers were
randomly selected and data extracted independently by
2 reviewers and compared to identify discrepancies if
any). Quality of included studies was assessed using ei-
ther the QUADAS tool for quality assessment of diag-
nostic studies included in systematic review [17], the
EPHPP quality assessment tool for quantitative studies
[18], or a specific tool for quality assessment of qualita-
tive studies [19].
The following data items were extracted: author (s)
and year of publication, intervention (name of POC
CD4 technology, training for test operators where men-
tioned), comparison (if applicable), population (age,
gender, HIV status), study setting (types of facility, loca-
tion/country), study design and sample size, and key
study outcomes of interest.
Definitions and assessment of acceptability and feasibility
Acceptability and feasibility are closely linked and affect
each other but they are not identical. Acceptability fo-
cuses on individual factors (provider and patient’s per-
spectives) while feasibility takes other system factors
(infrastructure, human resource, policy) into account.
Thus, one test could be acceptable to both provider and
patient, but may not be feasible to be deployed in a
specific setting (for example if a test device requires
constant electricity supply or dedicated, well trained
technicians to operate them). To assess acceptability
and feasibility of POC CD4 testing in field settings, a
conceptual framework initially developed to explore the
feasibility, acceptance and use of a rapid diagnostic test
for malaria [20] has been adapted for use in this study.
From the service provider’s perspective, acceptability is
assessed by the ability to understand how to correctly
perform a POC CD4 test, their willingness to carry out
the test when necessary as part of their daily work and
their belief that the test is relevant to their work and
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test result is accurate. From patient’s perspective, ac-
ceptability is influenced by their willingness to have the
test performed on themselves, their belief that the test
is convenient to take and relevant in determining their
CD4 count. Feasibility depends on acceptability and the
presence or absence of supporting system factors such
as training, monitoring/supervision, supplies, infrastruc-
ture such as space, light, water etc. that enable the imple-
mentation of POC CD4 testing in the field.
Based on this concept, the following pre-defined mea-
surements were used to assess acceptability (1) uptake of
POC CD4 testing: the proportion of individuals who
accept a POC CD4 test (having blood samples drawn for
POC CD4 test) of the total number of individuals who
have been confirmed HIV positive and offered CD4 test-
ing; (2) reported attributes of the POC CD4 test relating
to day-to-day field operation from the relevant stake-
holders’ perspectives (clients/patients, service providers,
health manager/policy makers). For assessing feasibility
the following measurements were used: (1) reported
system factors associated with or having effect on
acceptability and feasibility of POC CD4 test in the
field, and (2) locally specific context and operational is-
sues affecting the deployment of POC CD4 testing.
Results
Study characteristics
The search identified 12 studies that reported informa-
tion and data on the outcomes of interest (acceptability
and feasibility) including 11 articles and one abstract, 11
of which were conducted in Sub-Saharan countries and
used Pima as a single intervention or as part of an inter-
vention program to improve HIV testing uptake and
linkage to care (Table 1). Overall, the quality of included
studies was considered between moderate and strong.
The QUADAS score ranged from 7 to 12 (of a max-
imum score of 14) with most of the studies scoring be-
tween 10 and 12. Using the EPHPP tool, two studies
were ranked as “moderate” and one as “strong”. One
study deployed both quantitative and qualitative methods,
and addressed most of the essential criteria listed in the
tool for appraising the quality of qualitative research.
Fig. 1 Selection process of included study for a systematic review of POC CD4 test
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Table 1 Characteristics of studies included in the review
Author (s), Year Study objective Study population/Study setting Study design/Sample size Sample/data collection Intervention
Galiwango, 2014 [26] To conduct a field evaluation
assessing the accuracy of Pima
HIV infected patients (pre and
experienced ART persons) at
field clinics of Rakai Health
Science Program in Rakai district,
Southern rural Uganda. Study
area has half a million population.
Program is a community-based
research organization with a
focus on HIV/AIDS and
reproductive health
Cross-sectional study
A total of 903 patients
were recruited among
which 258 (28.5 %)
patients were on ART
Venous blood samples collected
by nursing team. Data was
collected for clinical purpose
and analyzed anonymously
Four Pima machines were
used (machines were moved
to testing site, located next
to clinics, everyday from
central Lab)
Prior to daily testing, normal
and low controls were run
on each machine. Tests were
run by qualified lab technicians
who received Pima usage
training
van Rooyen, 2013 [21] To conduct assessment on
effect of a home-based
counseling and testing
program that included POC
CD4 testing on (1) high HIV
testing coverage (2) identify
newly infected or unaware
HIV cases (3) reduce barriers
to care and (4) increase access
and adherence to ART
Known HIV-positive individuals
older than 18 years in KwaZulu-
Natal, South Africa. Study
population characterized by
high unemployment, low per
capita income; and very high
HIV prevalence (23.5 % among
people aged≤ 25). Study area
was within walking distance
of a primary health center
and ART clinic
Prospective cohort study
with one, three and six
months follow-ups by
lay counselors to evaluate
outcomes
281 households enrolled,
671 adults consented
and tested. Among 201
HIV infected participants,
193 had POC CD4 test in
addition to CD4 lab-Cyflow.
POC CD4 testing was conducted
at home using finger-prick blood
sample. Venous blood samples
were collected for BD
FACSCalibur
Pima (as part of home-based
counseling and testing program
included POC CD4 testing,
facilitated counseling and
referrals)
POC CD4 testing was
conducted in the home at the
same visit when positive HIV
rapid test was obtained. POC
test run by lay counselor/nurse
assistant; training of test
operators was not reported
Mtapuri-Zinyowera,
2013 [24]
To document experience in
implementation of Pima in
maternal and new-born
child health setting in
Zimbabwe
Clients (HIV positive women,
lactating mothers, their families
and other users) of health
facilities with high-volume ANC
visits of > 100 pregnant women
seen/month located in 7 districts
(five in each district) in Zimbabwe
with and without Pima machines
Key informants: relevant project
staffs, MNCH staffs, counselors,
lab staffs and ART personnel
Cross-sectional study
346 individuals were
interviewed. Questionnaires
were administered to
23 staff members, 62
trained POC users.
Observation tools was
applied to 22 trained
users. Client exit
questionnaire was
administered to 142
clients of POC sites and
42 clients of non-POC sites. 1
client FGD conducted in each of
7 districts. Data of 207 client’s
records was extracted from 45
facilities
Primary data was collected
through face-to-face interviews,
focus group discussion and
observation using audio
recorders and cameras (with
verbal consent). Secondary data
was extracted from medical
records xxx
Pima Implemented at 35 ANC
high-volume health facilities
to provide CD4 count to HIV
positive pregnant women and
their families in hard to reach
areas. Health care cadre and
training of test operators
not reported
Larson, 2012 [22] To assess the impact of
mobile HIV counseling and
testing program on the
proportion of patients
completing referral visit
within 8 weeks of HIV
testing
Adult HIV positive patients
diagnosed between May and
November 2010 in a mobile
HIV testing program (called
ACCESS VCT) with 2 mobile
units (with tents) to conduct
HCT at sites (taxi rank, shopping
mall) in Gauteng Province,
South Africa
Retrospective cohort study
A total of 508 patients were
diagnosed with 311 patients
were offered POC CD4 and
197 patients were not
Data was drawn retrospectively
from routinely collected medical
records kept by the ACCESS
VCT program and completed
in Feb 2011 allow for 8 weeks
follow-up for all HIV positive
patients
Four Pima devices were used
in the same mobile location
with each assigned to one
nurse. With 6–10 nurses
present during the day of
testing patients were
randomly assigned on a
first-come first-serve basis;
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Table 1 Characteristics of studies included in the review (Continued)
training of test operators
not reported
Glencross, 2012 [31] To report and compare the
performance of Pima in
laboratory or typical South
African primary health
HCT clinics
Adult HIV patients attending
(1) Hospital based antenatal
HCT clinic in Johannesburg-
phase II (2) Two Primary health
care HCT clinic in Limpopo
province-phase IIIA; and (3) Inner-
city primary health care clinic in
Johannesburg, South Africa-phase IIIB
Cross-sectional study
Phase II: N = 91
Phase IIIA: N = 96
Phase IIIB: N = 139
Both venous and capillary blood
samples were collected
Pima operators (nursing
personnel) were trained by
the suppliers prior to
commencing testing, according
to methods defined by the
manufacturer. Daily quality
control was performed before
commencing daily testing
Thakar, 2012 [25] To assess the use of Pima
at 21 ART centers in India
HIV positive patients aged 18–60
attending 21 ART centers in
different parts of India having
minimum (5-10/day) to moderate
(25-30/day) patient load.
Cross-sectional study
Total of 1790 participants
were consecutively
enrolled in 21 centers
(5–10 HIV positive
patients from each centre)
Both venous and capillary
blood samples were collected
Technologists were trained for
two days for finger prick
sample collection & CD4
count estimation using Pima
analyzer including the use of
calibrators. Samples were run
after low/normal control
cartridge give acceptable
values
Manabe, 2012 [27] To evaluate performance of
Pima in both laboratory and
non-laboratory environment
HIV infected patients at Adult
Infectious Diseases Institute Clinic
within the Mulago Hospital
Complex in Kampala, Uganda
Cross-sectional study
N = 206.
Both venous and finger-prick
blood samples were collected
by study nurse
CD4 counts were performed
using 4 Pima devices. Duplicate
measurements were performed
on both capillary and venous
samples using 2 different
devices. Test operator cadre
and training not stated
Jani, 2011 [28] To assess the ability of nurse
to produce accurate results
with POC test in primary health
care settings providing ART
Documented HIV infected
individuals from general patient
population attending 2 primary
health care setting providing a
range of health services including
ART in Maputo, Mozambique
Cross-sectional study
N = 697.
Participants provided finger-
prick (for POC tests) and
venous blood (for lab-based
tests)
Pima POC CD4 test operators
were nurses in primary health
clinics trained by the
manufacturer. Manufacturer
provided internal quality
control and all POC instruments
passed external qulity control
assessment during study period
Mtapuri-Zinyowera,
2010 [23]
To evaluate the use of Pima
and the ability of both nurses
and laboratory technicians to
run POC CD4 test
Newly diagnosed HIV positive
patients at a VCT center at New
Africa House in Harare, Zimbabwe
Cross-sectional study
N = 165.
Participants provided finger-
prick (for POC tests) and
venous blood (for lab-based
tests).
Two Pima devices were used.
Nurses and laboratory
technicians equally run POC
CD4 tests (50/50) on each
device.
All test operators were formally
trained on the Pima device and
sample collection methodology
for half a day
Wade, 2014 [30] To assess performance and
operational characteristics
of Pima
HIV infected patients presenting
for routine CD4 testing at
infectious disease clinic in Dar
es Salam (Tanzania)
Cross-sectional study
N = 200.
Both capillary blood (Pima)
and venous blood
(FACSCalibur) were collected
Pima test operator cadre and
training not reported. Pima
testing procedures were not
described
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Table 1 Characteristics of studies included in the review (Continued)
Mwau, 2014 [7] To evaluate the technical
performance of MyT4
POC CD4 test
HIV infected patients ≥ 18 years
old at comprehensive HIV care
clinics of 2 health care facilities
in Busia county of Western
province, Kenya
Cross-sectional study
N = 276.
Finger-prick blood samples
(for MyT4 test) and venous
blood samples for conventional
CD4 tests collected.
All samples were collected and
tested using MyT4 POC CD4 by
trained health care staffs (nurses
and lab technicians)
Training for staff not reported
Arnett N, 2013 [29] To assess healthcare worker
acceptance and ability to
perform POC CD4 test
HIV infected patients from 5
PMTCT and HIV treatment sites
in Dar-es-Salaam, Tanzania
Cross-sectional study
1060 patients provided blood
specimens, 11 HCWs interviewed
Each participant provided 3
samples: (1) venous (1) finger-
prick directly to PIMA cartridge
and (1) finger-prick collected
into Microtube
Pima POC CD4 tests run by
trained healthcare workers
HCT: HIV Counseling and Testing; ANC: Antenatal clinic; MNCH: Maternal and new-born child health; ART: Antiretroviral therapy; PMTCT: Prevention of mother to child transmission
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Acceptability and feasibility of POC CD4 test
Only one of the included studies, presented as a confer-
ence abstract, aimed to assess acceptability of a POC
CD4 test from the healthcare workers’ perspective. All
other studies primarily assessed accuracy and/or effect
of POC CD4 on HIV program or patient related out-
comes, and provided additional data related to accept-
ability and feasibility of POC CD4 testing under field
conditions (Table 2).
Patient perspectives
Available data suggest that the Pima test was highly ac-
ceptable across study settings. Acceptance rates ranged
from 90 % to 100 % when offered either at the home, via
mobile HIV counseling and testing or in permanent vol-
untary counseling and testing settings [21–23]. Patients
appreciated having on-site CD4 testing availability. One
participant reported: “They used to collect our blood
and send it somewhere, hence that will take some days
but as for now there is a big difference, we now receive
our results there and then” [24]. In terms of preference re-
garding the method of blood sampling, the findings of one
study in India [25] suggested that study participants prefer
to give venous blood samples versus finger-prick because
of the requirement for other blood tests (which can only
be performed with venous blood) and fear of being sub-
jected to the discomfort of multiple pricks with more pain
if sufficient volume is not obtained in one prick.
Provider perspectives
One study which employed qualitative research methods
in 35 maternal and new-born child health (MNCH)
settings in Zimbabwe [24] reported health personnel
expressed a preference toward performing POC CD4
testing (Pima) as it was efficient in resource use, user-
friendly and responded well to patients’ needs: the ma-
chine “used fewer resources (syringes and needles),
and less technical expertise was needed” to run the test
and it was “catering for all types of clients”; finger-
prick sampling was reported as “less traumatizing to
the patients as less blood is taken for immediate use”
and “no suspicion that blood was used for other pur-
poses”. The Pima machine was reported as portable,
compact, easy-to-use, battery operated with 3–4 h backup
providing feasibility for use in non-laboratory settings
[21, 25–27] and by non-laboratory technicians [23, 28].
However, relatively low throughput capacity, frequent
error codes, cartridge rejection before expiration date
and increased technical breakdown after one year of
operation at a busy site were also reported as limita-
tions of the Pima technology [24]. Healthcare workers
also noted that a full blood count is required to identify
type of antiretroviral drugs patients can be prescribed
and this cannot be done with a finger-prick sample; also
problems with test errors may lead to multiple pricks
being required [24]. In another study conducted at five
Prevention of Mother to Child Transmission (PMTCT)
and HIV/AIDS care and treatment clinics in Tanzania,
73 % (8/11) of health care workers who were inter-
viewed named venous blood as their preferred sample
collection method and 100 % (11/11) trusted Pima-
venous test results [29].
Influencing factors
Human resource shortage is a major factor that influ-
ences feasibility and acceptability of POC CD4 in field
settings. It was suggested that the introduction of onsite
POC CD4 testing would increase the workload of health
personnel at clinical settings and this could be consid-
ered the most prominent challenge in terms of feasibility
and acceptability in the context of no financial incentives
or additional staffing could be provided [24, 28]. Train-
ing for health care staff on POC CD4 testing was reported
as another factor that might influence acceptability and
feasibility. In addition to training of test operators, training
for health managers is also required. Senior health staff re-
ported that it was not feasible for them to monitor test op-
erators on a test on which they were not trained: “it’s
difficult for me to supervise something I don’t know
about” and “it’s downgrading to received instruction
from a junior” [24]. The internal quality control and
performance monitoring were also reported as critical
factors to ensure on-going reliability and acceptability
of POC CD4 testing in clinic settings where external
quality control is a challenge because of the remoteness
of the sites [27, 30, 31].
Discussion
The findings of our review show that there is relatively
limited data on acceptability and feasibility of POC CD4
testing, with data only available for the Pima test; no
other current commercially available POC CD4 tests
[32] have published data on acceptability and feasibility
in field settings. For Pima, the available data consist-
ently demonstrates that it is feasible to deploy for
decentralization of CD4 testing through different
models of service delivery. However, there are some is-
sues related to the implementation of Pima that might
influence acceptability and feasibility of the test that re-
main unanswered. From the patient’s perspective no
qualitative data were available to capture the willing-
ness of patients to choose a POC CD4 test over a
standard flow cytometric CD4 test when offered, or the
patient’s belief in the accuracy or relevance of POC
CD4 testing in identifying treatment eligibility or re-
sponse to treatment. One study [22] reported 10 % of
patients declined the offer of POC CD4 testing and
chose standard CD4 testing at referral clinics but
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Table 2 Acceptability and feasibility of POC CD4 test
Author (s), Year Technologies Proportion of HIV patients
accepted POC CD4 test
when offered
Reported attributes of POC CD4
test related to day-to-day field
operation
System Factors associated with/having
effect on acceptability/feasibility of
POC CD4 test
Locally specific context and operational
issues which affect the deployment
of POC CD4 test
Galiwango, 2014 [26] Pima Easy to use; enable same day,
on-site immunological
assessment and result
communication
In busy clinic, it requires 2–4
machines with additional
technician to complete
patient testing
van Rooyen, 2013 [21] Pima Highly acceptable at the time
of learning about HIV test result
(96 % of identified HIV positive
individuals accepted, tested
and received POC CD4 count
result at a HBCT visit
Feasible to be conducted at
homes, as part of home-based
HIV counseling and testing
program, in a rural South
African setting
Mtapuri-Zinyowera, 2013 [24] Pima Relatively low throughput,
frequent error codes and
cartridge rejection before
expiration date. Increased
technical breakdown after 1
year of operation at busy sites;
major breakdowns include
hardware and alignment and
loss of camera focus
25 % of users reported having
some challenges after machine
installation of which 67 % (of
cases) were resolved by the
Manufacturer and 33 % by users
Users reported training was useful
and relevant to day-to-day operation.
Training for supervisor is needed to
monitor staff performance. External
quality control was a challenge
because of remoteness of sites
Challenges with finger-prick
sampling is also noted including that
it cannot be used for full blood
count (required to determine types
of ARVs patient can take), high error
rate led to multiple finger-prick
exposing patient to more pain
Staff workload was the most
prominent challenge
reported by users (multiple
tasks and increased workload
without compensation); task
shifting should be considered
given prospect of additional
staff employment is low
Larson, 2012 [22] Pima When offered a rapid POC
CD4 test in a routine mobile
HCT setting, acceptance among
patients is high (90 %); only
32 /311 (10.3 %) patients
declined the offer of POC CD4
Glencross, 2012 [31] Pima Negative impact of (poor) capillary
blood sampling on POC CD4 test
performance: Capillary sampling
demands absolute diligence and
stringency of sampling technique.
Ongoing dedicated training as well
as implementation of systems for
monitoring and evaluation of testing
is strongly recommended
Thakar, 2012 [25] Pima Users expressed that PIMA was
compact and hence could fit in
the small space available at the
centers. It is battery operated,
showed a battery backup of
Study participants preferred to give
venous blood sample because of
requirement of blood collection for
other investigations using venous
blood and a fear of being subjected
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Table 2 Acceptability and feasibility of POC CD4 test (Continued)
3–4 h eliminating requirement
of continuous electricity
to multiple pricks if sufficient volume
of blood is not obtained in a single
prick
Manabe, 2012 [27] Pima Easy-to-use, portable, relatively
fast device to test CD4+ T cell
counts in the field
Quality control and observed
practical training for test operators
would be required to ensure that
good volume and flow of blood
(capillary) is obtained
Jani, 2011 [28] Pima Essential WHO-recommended
ART staging and monitoring
diagnostic tests can be accurately
conducted at primary health
care clinic level by non-laboratory
staff using POC CD4 test
Operators should be trained for
finger prick testing and their
performance should be regularly
monitored as training and monitoring
has been shown to be essential to
the ongoing reliability of other POC
CD4 test
Implementation of POC CD4
in primary health care clinics
requires careful planning. Task
shifting of ART services to
community clinics places
additional strain on the
workloads of nurses and other
healthcare workers that may
be unsustainable
Mtapuri-Zinyowera, 2010 [23] Pima The offer of POC CD4 testing
within post-test counseling
was accepted by almost all
eligible clients, even within
the context of a study and
the need to provide
informed consent.
POC CD4 testing can be
performed in non-laboratory
setting by non-laboratory
technicians (nurses)
It is important to ensure that Pima
test operators are well trained on
finger-prick sample collection.
Preliminary observations in this study
suggest that incorrect finger-prick
sampling affects the reliability of POC
CD4 results
Wade, 2014 [30] Pima Significant contribution of operators
to variability of POC CD4 test results:
dedicated training for test operators,
particularly on capillary blood
sampling is required to ensure quality
of POC CD4
Mwau, 2014 [7] MyT4 Relatively high throughput:
over 20 tests/6 h health facility
working day
Implementation would be
most effective by assigning a
dedicated full time operator
Arnet N, 2013 [29] Pima 100 % (11/11) HCW interviewed
trust Pima venous CD4 results;
91 % (10/11) for Pima Microtube
and 82 % (9/11) for Pima direct.
The most preferred sample
collection method was Pima
venous 73 % (8/11)
HBCT home-based HIV counseling and testing
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reasons for their preference was not studied. From the
health service provider’s perspective, a number of issues
need to be addressed in terms of acceptability and feasi-
bility to provide insights into future implementation of
the test. Although the device was reported as being
easy-to-use, a reported high error rate and frequent test
operator errors raised questions about the health
workers’ ability to correctly perform the test in their
daily working environment. Information on the training
and supervision of test operators that would allow as-
sessment of their capacity to follow testing procedure
and perform the test correctly is lacking. The prefer-
ence of health workers toward venous blood collection
for CD4 testing also needs further studies to identify if
this preference is due to the health workers’ belief in
the validity of the test, difficulties involved with capil-
lary blood sampling or other logistic issues related to
blood testing in field settings. Lastly, human resources
shortage represents a major challenge. The introduc-
tion of POC CD4 testing at primary healthcare level
has been reported to be associated with increased
work-load for health staff and while the provision of
this service may well response to patients’ needs and
improve quality of HIV treatment and care, the ques-
tion remains is how to provide effective and sustainable
POC CD4 testing service in busy primary clinic settings
without overburdening the already strained healthcare
providers. All these are important issues that need to
be studied and factored into the planning process to
guide future implementation of the test in remote and
disadvantaged areas.
Although data was only available for Pima POC CD4
testing, some lessons could be learned for future plan-
ning and implementation of POC CD4 testing in LMICs.
First, like other rapid diagnostic tests the validity or ac-
curacy of POC CD4 test as perceived by the end users
(health care provider and patient), will affect acceptance
and use of the test in the field [20]. As accuracy and effi-
cacy of the test are influenced by the test operators’
practical skills, the importance of quality training on
POC CD4 testing for health professionals, both test op-
erator and supervisor, must be recognized and infra-
structure to support this should be adequately addressed
before introduction and scale up of any POC CD4 tech-
nology [33]. This remains true for all POC tests that
could be considered “quick” and “easy” but often require
comprehensive training and supervision to ensure diag-
nostic test accuracy under field conditions [34, 35].
Without standardized quality training packages delivered
to health workers in these clinics, ensuring competency
standards are obtained by all test operators and their su-
pervisors, and without on-going internal quality assur-
ance systems in place it is impossible to rule out any
potential operator-induced bias. Second, the preference
toward a specific type of blood sample may also influ-
ence the acceptability and feasibility of a POC CD4 test.
This preference may come from either the health service
provider’s or patient’s views including challenges with
one type of blood sampling, the need for a large amount
of blood for other blood tests, or the health worker’s be-
lief in accuracy of the test with one type of blood over
the other. For POC CD4 tests that can be used with ei-
ther type of blood sample, this would require further
study to identify technical and programmatic solutions
for extending test applicability in the field. Third, POC
technologies are designed to be user friendly and be eas-
ily operated by low-to-middle level healthcare cadres. In
addition to the importance of training for health staff,
discussed above, their workload upon introduction of
POC CD4 testing is an important issue to consider. The
reality is that in some of the highest volume clinics in
low-resource settings, it is the nurses, midwives and
counselors who have the highest workload. Therefore, it
is recommended that patient and staff work flow should
be thoroughly studied and work load issues appropri-
ately addressed through additional incentives, staffing or
task shifting to ensure the effectiveness, efficacy and sus-
tainability of POC technology when introduced into
busy clinical settings.
The future role and impact of CD4 testing in general
and POC CD4 testing in particular need to be consid-
ered from both technical and programmatic perspec-
tives. In order to achieve the newly proposed sustainable
development goal of ending the HIV/AIDS epidemic by
2030 [36], and with evidence showing positive clinical
impact of ART for patients with CD4 count > 500 cells/
μl [37], a policy shift toward recommendation of ART
initiation for all HIV infected individuals regardless of
CD4 count has recently been announced by WHO [38].
However, scaling up of ART programs in low-resource
settings may risk low adherence and retention to care
rates if critical health system factors such as well-trained
health staff, well-functioning patient monitoring and ap-
propriate support systems are not in place [39]. A suc-
cessfully scaled up treatment program, therefore, will
require innovative and effective models of service deliv-
ery (such as integration and decentralization of care),
strong procurement and supply chain management, suf-
ficient laboratory and/or point-of-care diagnostic ser-
vices to monitor clinical treatment outcomes, HIV viral
load and drug resistance and antiretroviral drug toxic-
ities. Most of these systems are not currently in place in
those LMICs mostly affected by the HIV epidemic and
could only be achieved through a gradual process of
health system strengthening. Therefore, in countries
where treatment for all is not currently feasible with the
available resources and current health system capacity,
CD4 testing is required to prioritize treatment eligibility
Pham et al. BMC Health Services Research  (2016) 16:343 Page 10 of 12
likely for those patients whose CD4 count is less than
350 cells/μl. Going forward, CD4 testing will still play an
important role in identifying patients who present late to
care for clinical management, for initiation and cessation
of prophylaxis and for management of patient responses
to ART even in countries where CD4-independent ART
initiation is being introduced.
This review has some limitations that should be con-
sidered in interpretation of the findings. First, assess-
ment of acceptability and feasibility was not the
primary objective of any of the included studies and in
a number of studies POC CD4 testing was only a part
of a more comprehensive program intervention. This
carries a risk of introducing bias as impact of the POC
CD4 test and its acceptability and feasibility could be
influenced by other interventions or implementation
strategies. Second, we included only published studies
in English and this inclusion may overlook data from
studies published in other languages or unpublished
data from evaluations conducted by government agen-
cies, local reference facilities or research institutions.
All but one of the included studies reporting outcomes
of interest use Pima as the index test and this presents
challenges in terms of generalizing the findings of the
review to other POC CD4 tests, as specific technical
and operational characteristics of each test will signifi-
cantly impact feasibility and acceptability of the test
from both service provider and patient perspectives. Of
note, these limitations cannot be overcome until more
data from field studies of different POC CD4 technolo-
gies are available.
Conclusions
Data is available for one of the POC CD4 tests on the
market, the Alere Pima CD4, and suggests that it could
be feasible to implement point-of-care CD4 testing in
non-laboratory settings in low and middle income coun-
tries. Further studies using other currently or newly
available POC CD4 tests in different geographical re-
gions are needed to inform in-country decision making
regarding the selection and adoption of a suitable test.
Qualitative studies on feasibility and acceptability are
needed to explore end users’ beliefs on the value of and
preference toward POC CD4 testing. Evidence regarding
supporting system factors such as training, monitoring,
supplies, and facility requirements should be available
and inform the planning process for the introduction
and scaling up of POC CD4 tests at primary health care
levels in low-resource settings.
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